[
  {
    "question": "Which is femoral nerve function:",
    "option_a": "hip flexion, knee extension, medial area of thigh decreased sensation",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroanatomy",
    "explanation": "The femoral nerve arises from the lumbar plexus (roots L2\u2013L4) and is responsible for innervating the muscles of the anterior thigh (notably the quadriceps, which extend the knee) and contributes to hip flexion (via the iliacus portion). It also provides sensory innervation to the anterior thigh and, via its saphenous branch, to the medial aspect of the leg. Damage or compression of the femoral nerve (from trauma, diabetic neuropathy, or entrapment) disrupts both its motor and sensory functions. The loss of quadriceps function compromises knee extension, while sensory deficits typically manifest in the skin areas supplied by its terminal branches. Although the classic sensory distribution is the anterior thigh and medial leg, exam questions may sometimes simplify the description as decreased sensation in the 'medial area of the thigh'. Patients with femoral nerve dysfunction are likely to exhibit weakness in knee extension, a diminished or absent patellar reflex, and areas of decreased sensation on the anterior thigh along with parts of the medial lower leg. These findings can aid in localizing the lesion to the distribution of the femoral nerve. Clinical evaluation involves a focused neurological exam (testing motor strength of the quadriceps, patellar reflex, and sensory examination). Differential diagnoses include injuries to other nerves such as the obturator nerve (which primarily affects thigh adduction and medial thigh sensation) and the lateral femoral cutaneous nerve (which affects lateral thigh sensation). Electrophysiological studies and imaging (such as MRI) may be used in ambiguous cases. First-line management is usually conservative, including physical therapy for strength and gait training and medications for neuropathic pain if required. In cases of nerve compression, further imaging and potential surgical intervention may be considered. In pregnancy and lactation, physical therapy remains a safe modality, and medications should be chosen carefully to avoid fetal or neonatal harm. Option A is correct because it appropriately identifies the key motor functions (hip flexion and knee extension) and the sensory distribution (although the wording mentions 'medial area of thigh,' which is a simplification of the typical anterior thigh and medial leg distribution). The other options are absent, so Option A stands as the most accurate response. 1. The quadriceps are innervated by the femoral nerve, and weakness in knee extension is a classic sign of its impairment. 2. The saphenous nerve, a branch of the femoral nerve, supplies sensation to the medial leg. Current clinical practice emphasizes careful neurological examination and use of nerve conduction studies when the diagnosis is uncertain. Updated guidelines support conservative management initially, with imaging reserved for atypical cases or when a compressive lesion is suspected.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "with destruction of the anterior hypothalamic nucleus you will find:",
    "option_a": "Insomnia And hyperthermia",
    "option_b": "hypersomnolence",
    "option_c": "REM sleep behavior",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroanatomy",
    "explanation": "The anterior hypothalamic nucleus, particularly the preoptic area, plays a crucial role in maintaining sleep and regulating body temperature through heat dissipation mechanisms. Destruction of the anterior hypothalamic nucleus disrupts the normal regulation of sleep and thermoregulation. Loss of its sleep-promoting signals contributes to insomnia, while impaired heat dissipation leads to hyperthermia because the body loses a key mechanism for activating cooling responses. Patients with lesions affecting the anterior hypothalamic nucleus may present with difficulty sleeping (insomnia) and episodes of hyperthermia due to an inability to appropriately regulate and lose excess body heat, linking the anatomical dysfunction to observable clinical symptoms. The diagnostic workup would include imaging studies (MRI) to localize hypothalamic lesions, as well as a thorough clinical history. Differential diagnoses might include other hypothalamic or pituitary disorders (e.g., hypothalamic hamartomas, inflammatory conditions) that can disrupt sleep and temperature control. Laboratory tests may be used to rule out systemic causes of hyperthermia. Management involves addressing the underlying cause of the hypothalamic damage if possible (e.g., tumor resection, management of inflammatory conditions). Symptomatic treatment may include environmental modifications for hyperthermia and sleep aids for insomnia. In pregnant or lactating patients, careful selection of medications that do not adversely affect the fetus or infant is critical; non-pharmacological sleep hygiene and temperature control measures are first-line options. Option A (Insomnia and hyperthermia) is correct because destruction of the anterior hypothalamic nucleus disrupts both sleep induction and thermoregulatory cooling mechanisms. The other provided options (such as hypersomnolence or REM sleep behavior disorder) do not match the known functions of this nucleus. 1. The anterior hypothalamus is vital for initiating sleep and promoting heat loss. 2. Disruption in hypothalamic function can lead to mixed clinical presentations combining neurological and systemic symptoms. Recent studies continue to highlight the importance of hypothalamic regulation in both circadian rhythms and thermoregulation. Updated research guidelines reinforce targeted investigation of hypothalamic lesions with advanced neuroimaging and call for individualized treatment strategies in affected patients.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "Scenario of LGM1B (laminopathy) with heart enzyme, what is the expected finding:",
    "option_a": "Contracture of elbow and ankle",
    "option_b": "",
    "option_c": ", which was marked, is incorrect because it does not describe an expected finding and appears to be an empty distractor.",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroanatomy",
    "explanation": "LGM1B refers to a form of laminopathy associated with mutations in the LMNA gene. Such mutations can manifest as a limb\u2013girdle muscular dystrophy (LGMD) phenotype overlapping with features seen in Emery-Dreifuss muscular dystrophy. Mutations in the LMNA gene affect the lamin A/C proteins, which are essential for the structural integrity of the nuclear envelope. This disruption leads to muscle fiber degeneration, early joint contractures (notably at the elbows and ankles), and a propensity for cardiac conduction abnormalities and cardiomyopathy. Patients with LMNA-related muscular dystrophies frequently present with early contractures (often at the elbows and ankles), progressive muscle weakness predominantly in the limb\u2013girdle distribution, and cardiac involvement evidenced by conduction defects or dilated cardiomyopathy. Elevations in heart enzymes may reflect cardiac muscle involvement. The diagnosis is supported by clinical examination (noting the pattern of contractures and muscle weakness), elevated muscle enzymes, cardiac evaluation (ECG, echocardiogram), and definitive genetic testing for LMNA mutations. Differential diagnoses include other forms of LGMD (such as sarcoglycanopathies) and classic Emery-Dreifuss muscular dystrophy, which have overlapping but distinct features. First-line management involves multidisciplinary care including physical therapy, orthopedic support (to manage contractures), and regular cardiac monitoring (ECG, echocardiogram). Due to high risk of arrhythmias, implantation of a pacemaker or defibrillator may be considered. In pregnancy and lactation, careful cardiac monitoring and medication adjustments (using drugs with established safety profiles) are necessary to prevent maternal cardiac events while minimizing fetal risk. Option A (Contracture of elbow and ankle) is the typical clinical finding in LMNA-related disorders such as LGM1B, making it the correct answer. Option C, which was marked, is incorrect because it does not describe an expected finding and appears to be an empty distractor. 1. Early contractures of the elbows and ankles are a hallmark of LMNA-related muscular dystrophies. 2. Cardiac involvement is a significant concern in laminopathies and requires lifelong surveillance. Recent guidelines emphasize routine cardiac screening for patients with LMNA mutations due to the risk of sudden cardiac death. Research continues to explore targeted molecular therapies, but current management remains supportive and multidisciplinary.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "Patient came with tongue pain and parasthesia, radiating to the neck, increased with neck movement, Dx?",
    "option_a": "tongue neck syndrome",
    "option_b": "Glossopharyngeal Neuralgia",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroanatomy",
    "explanation": "Neck-tongue syndrome (sometimes referred to as tongue-neck syndrome) is a rare disorder characterized by neck pain accompanied by paresthesia or pain in the tongue, typically triggered or exacerbated by neck movement. This syndrome is thought to result from an abnormality or irritation at the craniocervical junction, potentially affecting the upper cervical nerve roots\u2014especially the C2 nerve\u2014which may influence sensory fibers that communicate with cranial nerves involved in tongue sensation. The phenomenon is usually triggered by sudden or sustained neck movements, which provoke the aberrant neural response. Patients with neck-tongue syndrome typically report pain in the neck radiating to the tongue along with abnormal sensations (paresthesias) that worsen with neck movements. This clinical presentation is distinct from other cranial nerve neuralgias in terms of its trigger (movement rather than swallowing or chewing) and localization. The diagnosis is largely clinical. Differential diagnoses include glossopharyngeal neuralgia (which classically presents with throat, ear, and posterior tongue pain triggered by swallowing) and other cervical radiculopathies. Detailed history, physical examination, and sometimes cervical spine imaging (MRI or CT) help to exclude other structural causes. Management is typically conservative. First-line therapy includes physical therapy, non-steroidal anti-inflammatory drugs (NSAIDs), and possibly muscle relaxants. In refractory cases, nerve blocks or other interventional pain procedures might be considered. For pregnant or lactating patients, non-pharmacologic therapies (physical therapy and careful activity modification) are preferred, while medications should be chosen based on established safety profiles. Option A, which indicates tongue-neck syndrome (i.e., neck-tongue syndrome), is correct as it directly describes the condition characterized by tongue pain and paresthesia that is aggravated by neck movement. Option B (Glossopharyngeal Neuralgia) is incorrect because that condition typically involves pain in the throat, ear, and posterior tongue with triggers such as swallowing or chewing rather than neck movement. 1. Neck-tongue syndrome is a rare but distinctive clinical entity where neck movement reproducibly triggers tongue dysesthesia. 2. It is important to differentiate this syndrome from glossopharyngeal neuralgia, which has a different trigger and pain distribution. While evidence is limited due to the rarity of neck-tongue syndrome, recent case reports and small series underscore the importance of a careful history and targeted cervical spine imaging to rule out other cervical pathologies. Current management remains primarily conservative, emphasizing physical therapy and symptomatic care.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Associated with SEGA:",
    "option_a": "Tuberous sclerosis",
    "option_b": "NF",
    "option_c": "Sturge weber syndrome",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neurogenetics",
    "explanation": "Subependymal giant cell astrocytomas (SEGAs) are benign brain tumors that most often occur in patients with tuberous sclerosis complex (TSC). TSC is a neurocutaneous syndrome characterized by the development of hamartomas in multiple organs including the brain, skin, heart, and kidneys. Mutations in the TSC1 or TSC2 genes lead to dysregulation of the mTOR pathway, which in turn causes abnormal cell growth and proliferation. The mTOR hyperactivation results in the formation of various hamartomatous lesions, including cortical tubers, subependymal nodules, and SEGAs. These tumors typically develop near the foramen of Monro and may cause obstructive hydrocephalus if they grow large enough. Patients with TSC often present in early childhood with seizures, developmental delays, and characteristic skin lesions (such as facial angiofibromas, shagreen patches, and hypomelanotic macules). The presence of a SEGA can lead to symptoms related to increased intracranial pressure, such as headache, nausea, and changes in behavior or consciousness. The diagnosis of TSC is primarily clinical, supported by neuroimaging and other investigations. Brain MRI is used to identify SEGAs and other intracranial lesions. Differential diagnoses include other neurocutaneous syndromes like neurofibromatosis (which has distinct features such as caf\u00e9-au-lait spots and neurofibromas) and Sturge-Weber syndrome (characterized by leptomeningeal angiomas and port-wine stains). Management of SEGAs in TSC includes regular neuroimaging surveillance. For asymptomatic or small lesions, a watch-and-wait approach may be adopted. Symptomatic SEGAs that lead to complications such as obstructive hydrocephalus may require surgical resection. Additionally, mTOR inhibitors (e.g., everolimus) are now recommended as a first-line therapy in many cases to reduce tumor size, with considerations for pregnancy and lactation (everolimus is generally not recommended during pregnancy and lactation; risks and benefits must be carefully weighed with specialist input). Option A (Tuberous sclerosis) is correct because SEGAs are a hallmark brain tumor in TSC. Option B (NF \u2013 Neurofibromatosis) and Option C (Sturge-Weber syndrome) are unrelated to the development of SEGAs. 1. Always consider TSC in pediatric patients presenting with seizures and characteristic skin lesions. 2. SEGAs are typically found near the foramen of Monro and can cause obstructive hydrocephalus. 3. mTOR inhibitors have emerged as an effective treatment alternative to surgery for SEGAs. Recent studies underscore the efficacy of mTOR inhibitors in reducing SEGAs size and stabilizing disease progression in TSC. Updated clinical guidelines now recommend incorporating mTOR inhibitor therapy as part of the management algorithm, especially for patients in whom surgery poses high risks.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Scenario for patient has exam findings of oculomotor apraxia",
    "option_a": "nalysis provided indicates that all listed options (A, B, C, D, E) are essentially 'None' of the expected causative or management strategies. The correct interpretation is that none of the individual options correctly pinpoint the etiology because OMA in this scenario is a marker for hereditary neurogenetic conditions. The marked answer of B fails to capture this nuance; therefore, the corrected answer is a combination of all options (A,B,C,D,E) representing that none of the provided answers individually are correct.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A,B,C,D,E",
    "subspecialty": "Neurogenetics",
    "explanation": "Oculomotor apraxia (OMA) is the inability to voluntarily and efficiently shift the gaze, particularly in the horizontal plane. It is frequently observed as a congenital or hereditary feature, often associated with various neurogenetic disorders. OMA results from dysfunction in the neural circuitry that coordinates voluntary eye movements, typically involving the frontal eye fields, parietal eye areas, and cerebellar connections. In hereditary forms, genetic mutations affect proteins crucial for the development and function of these pathways. Clinically, patients with OMA have difficulty initiating saccades and may compensate by using head movements to redirect their gaze. This finding is characteristic of certain inherited ataxias and neurogenetic conditions such as ataxia-telangiectasia or other hereditary oculomotor disorders. The evaluation of OMA includes a detailed neurological examination focusing on eye movements and saccadic initiation. Differential diagnoses include acquired causes such as stroke, neurodegenerative diseases, or structural brain lesions. Neuroimaging (MRI) may be used to exclude these acquired causes. Management of OMA is generally supportive. Strategies include vision therapy, occupational therapy, and interventions to help compensate for the deficit. There is no specific pharmacological treatment for OMA itself. In the setting of an underlying neurogenetic syndrome, addressing the broader condition is key. In pregnancy and lactation, management remains supportive and tailored to the individual\u2019s functional needs, as there are no contraindicated medications specifically for OMA. The option analysis provided indicates that all listed options (A, B, C, D, E) are essentially 'None' of the expected causative or management strategies. The correct interpretation is that none of the individual options correctly pinpoint the etiology because OMA in this scenario is a marker for hereditary neurogenetic conditions. The marked answer of B fails to capture this nuance; therefore, the corrected answer is a combination of all options (A,B,C,D,E) representing that none of the provided answers individually are correct. 1. OMA should prompt clinicians to consider underlying neurogenetic conditions rather than isolated structural lesions. 2. Compensation by head thrusts is a common adaptation in patients with OMA. 3. A thorough neurological examination is essential to differentiate congenital from acquired causes. Current research emphasizes the genetic basis of congenital OMA, with recent genetic studies continuing to identify novel mutations associated with hereditary ocular motor dysfunction. Updated guidelines recommend a comprehensive evaluation using both clinical and genetic assessments to achieve an accurate diagnosis.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Same scenario of CADASIL, which gene?",
    "option_a": "NOTCH3 gene (chromosome 19)",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neurogenetics",
    "explanation": "CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy) is a hereditary small vessel disease that predominantly affects the cerebral vasculature. Mutations in the NOTCH3 gene on chromosome 19 cause an abnormal accumulation of granular osmiophilic material within the walls of small arteries, leading to progressive degeneration of vascular smooth muscle cells. This results in thickened vessel walls, reduced cerebral blood flow, and ultimately, subcortical ischemia and leukoencephalopathy. Patients with CADASIL typically present with recurrent strokes, migraine headaches (often with aura), mood disturbances, and progressive cognitive decline. The clinical course is variable and often leads to significant disability. Diagnosis is established via a combination of clinical history, characteristic MRI findings (e.g., white matter hyperintensities in the anterior temporal poles and external capsules), and confirmed by genetic testing for NOTCH3 mutations. Differential diagnoses include other causes of small vessel disease such as hypertensive arteriopathy and demyelinating diseases like multiple sclerosis. Management is primarily supportive and focuses on controlling vascular risk factors. There is no curative treatment; strategies include antiplatelet therapy for stroke prevention, management of migraine symptoms, and addressing cognitive and psychiatric complications. In pregnancy and lactation, treatment should be tailored to minimize risk, with careful selection of medications that are safe in these contexts. Option A, which identifies the NOTCH3 gene mutation on chromosome 19, is correct. Other options (B, C, D) are either not provided or incorrect concerning the genetic basis of CADASIL. 1. CADASIL should be suspected in young patients with unexplained strokes and a strong family history of early-onset vascular events. 2. MRI findings, particularly the involvement of the anterior temporal lobes, are highly suggestive of CADASIL. 3. Genetic testing for NOTCH3 mutations confirms the diagnosis. Recent studies have reinforced the diagnostic value of MRI and genetic testing in CADASIL. While treatment remains supportive, emerging research is focused on understanding the molecular pathways involved, which may eventually lead to targeted therapies.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Scenario of fragile X syndrome",
    "option_a": "is correct as it appropriately identifies the FMR1 CGG repeat expansion as the mutation responsible for Fragile X syndrome. Incorrect options might mistakenly suggest mutations in other genes (e.g., MECP2) or misrepresent the inheritance pattern.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neurogenetics",
    "explanation": "Fragile X syndrome is a genetic disorder and the most common inherited cause of intellectual disability. It results from a mutation involving a trinucleotide (CGG) repeat expansion in the FMR1 gene. The mutation in the FMR1 gene leads to a full mutation state when the CGG repeat exceeds 200 repeats. This expanded repeat results in hypermethylation of the gene and subsequent silencing of the fragile X mental retardation protein (FMRP), which is crucial for normal synaptic development and plasticity. Clinically, patients with fragile X syndrome present with intellectual disability, facial dysmorphisms (such as a long face, large ears), macroorchidism in post-pubertal males, and behavioral issues including autism spectrum behaviors. These features vary in their expression and severity between individuals. The diagnosis is confirmed by genetic testing using PCR and Southern blot analysis to determine the number of CGG repeats in the FMR1 gene. Differential diagnoses include other causes of intellectual disability such as Rett syndrome (caused by MECP2 mutations) and other genetic syndromes; however, the pattern of inheritance and clinical presentation help differentiate them. Management of fragile X syndrome is multidisciplinary and supportive, focusing on educational interventions, behavioral therapy, and management of associated conditions such as anxiety and ADHD. Pharmacological treatments may include stimulants, SSRIs, or atypical antipsychotics when indicated. Genetic counseling is essential for families, especially regarding reproductive planning. In pregnancy and lactation, care providers should offer preconception counseling and discuss the implications of carrier status, though no specific medication for fragile X is contraindicated solely based on these states. Option A is correct as it appropriately identifies the FMR1 CGG repeat expansion as the mutation responsible for Fragile X syndrome. Incorrect options might mistakenly suggest mutations in other genes (e.g., MECP2) or misrepresent the inheritance pattern. 1. Fragile X syndrome is the most common inherited cause of intellectual disability and autism spectrum disorders in males. 2. The typical physical features (long face, large ears, macroorchidism) may be subtle in early childhood. 3. Early intervention and multidisciplinary management improve outcomes. Current guidelines emphasize early detection and intervention in fragile X syndrome. Recent research continues to explore targeted treatments that may modify neurodevelopmental outcomes, while genetic counseling remains a cornerstone of management for affected families.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Patient with hypomelanotic lesions:",
    "option_a": "(NF1) is incorrect because NF1 typically presents with hyperpigmented caf\u00e9",
    "option_b": "(NF2) is also incorrect since NF2 is characterized by bilateral vestibular schwannomas with minimal skin manifestations. Option c (TSC) is correct, as the presence of hypomelanotic macules (ash leaf spots) is a hallmark of this condition.",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "c",
    "subspecialty": "Neurogenetics",
    "explanation": "Tuberous Sclerosis Complex (TSC) is a neurocutaneous disorder that often manifests with distinctive hypomelanotic macules, commonly known as 'ash leaf spots'. These skin findings are one of the major diagnostic criteria and often appear early in life, prompting further evaluation for multi\u2010system involvement. TSC is caused by mutations in either the TSC1 or TSC2 genes, which normally encode hamartin and tuberin respectively. These proteins regulate the mTOR pathway, a critical mediator of cell growth and proliferation. Loss of normal function leads to dysregulated cellular proliferation and the formation of benign tumors and skin lesions in various organs, including the brain, kidneys, and heart. Hypomelanotic macules in TSC appear as well\u2010demarcated light patches on the skin. They are often detectable using a Wood lamp examination. In addition to hypomelanotic lesions, patients may have seizures, developmental delays, and other systemic findings such as renal angiomyolipomas. These multi-system features help differentiate TSC from other neurocutaneous disorders. The differential diagnosis includes Neurofibromatosis type 1 (NF1), which is associated with caf\u00e9-au-lait spots (hyperpigmented lesions) and axillary freckling, and NF2, which predominantly presents with nervous system tumors and minimal skin findings. A thorough clinical examination combined with genetic testing and imaging (e.g., brain MRI) may be employed to confirm the diagnosis of TSC. Management is multidisciplinary. For neurological manifestations such as seizures and cognitive impairments, antiepileptic drugs and developmental therapies are used. mTOR inhibitors (e.g., everolimus) are recommended for managing specific manifestations, such as renal angiomyolipomas and subependymal giant cell astrocytomas. In pregnant or lactating women, the use of mTOR inhibitors is generally approached with caution due to potential teratogenic risks, and therapy should be tailored according to current obstetric guidelines. Option a (NF1) is incorrect because NF1 typically presents with hyperpigmented caf\u00e9-au-lait macules rather than hypomelanotic lesions. Option b (NF2) is also incorrect since NF2 is characterized by bilateral vestibular schwannomas with minimal skin manifestations. Option c (TSC) is correct, as the presence of hypomelanotic macules (ash leaf spots) is a hallmark of this condition. 1. Ash leaf spots in TSC are best visualized with a Wood lamp examination. 2. TSC has multi-system involvement, so early diagnosis can aid in surveillance for neurological and renal complications. Recent guidelines stress the importance of early genetic testing and neuroimaging in TSC. There is increasing evidence supporting the use of mTOR inhibitors in selected patients, although their use in women of childbearing age requires careful risk-benefit analysis due to potential teratogenicity.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Wilson case, with Kayser\u2013Fleischer ring & pyramidal sign, confirm Dx:",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "(Serum copper & ceruloplasmin) is the correct and essential diagnostic step. Option a (MRI brain) is useful for assessing neuro involvement but is nonspecific. Option b (liver biopsy) is reserved for cases where biochemical tests are inconclusive and is invasive. Option c (CT scan) has limited sensitivity and is not used for confirming the diagnosis.",
    "option_e": "",
    "correct_answer": "d",
    "subspecialty": "Neurogenetics",
    "explanation": "Wilson disease is a hereditary disorder of copper metabolism resulting from mutations in the ATP7B gene. The disease leads to toxic accumulation of copper in various tissues, primarily the liver and brain. Defective biliary excretion of copper causes its accumulation within hepatic cells. This surplus copper eventually spills over into the bloodstream and deposits in the brain, particularly in the basal ganglia, leading to neuropsychiatric manifestations. The deposition of copper in the eyes leads to the characteristic Kayser-Fleischer rings. Clinically, patients present with neurological signs such as a pyramidal tract involvement and movement disorders in combination with hepatic dysfunction. The presence of Kayser-Fleischer rings is highly suggestive of Wilson disease and typically accompanies these manifestations. The diagnosis is primarily confirmed biochemically with serum copper and ceruloplasmin measurements. Low serum ceruloplasmin, decreased total serum copper, and elevated levels of free copper are hallmark findings. While liver biopsy for hepatic copper quantification is considered the gold standard when results are equivocal, it is more invasive. Imaging modalities like MRI can support the evaluation by assessing brain involvement but are not diagnostic on their own. First-line treatment involves chelation therapy using agents such as D-penicillamine or trientine to promote copper excretion, along with zinc therapy to block copper absorption in the gastrointestinal tract. In pregnant or lactating women, treatment continues with careful monitoring as the safety profile of certain chelators may require adjustments and monitoring under specialist guidance. Option d (Serum copper & ceruloplasmin) is the correct and essential diagnostic step. Option a (MRI brain) is useful for assessing neuro involvement but is nonspecific. Option b (liver biopsy) is reserved for cases where biochemical tests are inconclusive and is invasive. Option c (CT scan) has limited sensitivity and is not used for confirming the diagnosis. 1. The combination of Kayser-Fleischer rings with neurological signs is strongly indicative of Wilson disease. 2. Biochemical testing (serum copper and ceruloplasmin) remains the cornerstone of diagnosis. Recent guidelines emphasize early diagnosis and treatment initiation. Studies continue to refine chelation protocols and monitor long-term outcomes, with ongoing research into optimizing therapies for special populations, including pregnant patients.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Case of ADHD & hyperpigmented brownish skin lesion with axillary freckling:",
    "option_a": "(NF1) is correct as it best fits the clinical picture of hyperpigmented caf\u00e9",
    "option_b": "(NF2) does not typically present with these skin manifestations, and Option C (Tuberous Sclerosis Complex) is characterized by hypomelanotic, not hyperpigmented, lesions.",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Neurogenetics",
    "explanation": "Neurofibromatosis type 1 (NF1) is an autosomal dominant neurocutaneous disorder characterized by multiple caf\u00e9-au-lait spots, freckling in skin folds (such as the axilla), and neurocognitive issues including attention deficit hyperactivity disorder (ADHD). NF1 results from mutations in the NF1 gene which encodes neurofibromin, a tumor suppressor protein that regulates the Ras/MAPK signaling pathway. Loss of neurofibromin function leads to abnormal cell proliferation and tumor formation, as well as the characteristic cutaneous manifestations. Patients with NF1 typically present with hyperpigmented caf\u00e9-au-lait macules (light to dark brown lesions) along with axillary or inguinal freckling. ADHD and other learning disabilities are common neurocognitive comorbidities, which further support the clinical diagnosis. The diagnosis is primarily clinical, based on the NIH criteria which include the presence of caf\u00e9-au-lait spots, neurofibromas, Lisch nodules on the iris, and characteristic freckling. Genetic testing may be used in uncertain cases to confirm the diagnosis. Management includes regular surveillance for complications such as optic pathway gliomas and malignant peripheral nerve sheath tumors. Supportive care for neurocognitive issues (including ADHD) is important, involving educational interventions and behavioral therapy. In the context of pregnancy, NF1 patients require close monitoring due to associated risks including hypertensive disorders and potential worsening of neurofibromas. Option A (NF1) is correct as it best fits the clinical picture of hyperpigmented caf\u00e9-au-lait spots with axillary freckling and ADHD. Option B (NF2) does not typically present with these skin manifestations, and Option C (Tuberous Sclerosis Complex) is characterized by hypomelanotic, not hyperpigmented, lesions. 1. Caf\u00e9-au-lait spots and axillary freckling are major diagnostic criteria for NF1. 2. Neurocognitive issues like ADHD are commonly associated with NF1 and may require multidisciplinary management. Recent recommendations stress early recognition of NF1 for proper surveillance and management, especially given the risk for tumor development and learning difficulties. Updated guidelines also discuss the genetic counseling implications for familial cases.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Case of NF1 with light brown macule, the name of skin lesion",
    "option_a": "(Caf\u00e9",
    "option_b": "(Lisch nodules) are benign iris hamartomas and are detected on ophthalmologic examination rather than through skin observation. Option c (Ash leaf spot) refers to hypopigmented lesions typical of tuberous sclerosis complex, not NF1.",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Neurogenetics",
    "explanation": "Caf\u00e9-au-lait spots are the classic light brown macules that are frequently observed in patients with Neurofibromatosis type 1 (NF1). They are one of the key cutaneous markers used in the diagnosis of NF1. The development of caf\u00e9-au-lait spots in NF1 is due to localized hyperpigmentation caused by an increase in melanin deposition without a corresponding increase in melanocyte proliferation. This reflects the underlying genetic defect in the NF1 gene, which leads to dysregulation of cellular growth pathways. In NF1, caf\u00e9-au-lait spots are typically present from early childhood and serve as a vital clinical clue. Their presence, especially when numbering six or more and of a certain size, strongly supports the diagnosis. They must be differentiated from other skin lesions such as ash leaf spots, which are hypopigmented and seen in tuberous sclerosis. The diagnosis is made clinically based on established criteria. A thorough physical examination should assess for the number, distribution, and size of the caf\u00e9-au-lait spots. Other features, such as Lisch nodules and neurofibromas, are also evaluated to confirm NF1. Management of NF1 is largely supportive, focusing on regular surveillance for potential complications such as optic pathway gliomas and skeletal abnormalities. Early intervention for developmental or learning challenges is recommended. In pregnant or lactating women with NF1, careful monitoring is essential given the increased risk of complications and the possibility of progression in tumor burden. Option a (Caf\u00e9-au-lait spot) is the correct designation for the light brown macule seen in NF1. Option b (Lisch nodules) are benign iris hamartomas and are detected on ophthalmologic examination rather than through skin observation. Option c (Ash leaf spot) refers to hypopigmented lesions typical of tuberous sclerosis complex, not NF1. 1. Caf\u00e9-au-lait spots in NF1 are an early and easily recognizable sign that can prompt further investigation. 2. A clear distinction between caf\u00e9-au-lait spots and other similar-appearing lesions (such as ash leaf spots) is essential for accurate diagnosis. Recent studies continue to explore the genotype-phenotype correlations in NF1, aiming to better predict disease severity and guide management. Current guidelines underscore the importance of multidisciplinary monitoring in NF1 to address both cutaneous and systemic manifestations.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Young male with progressive external ophthalmoplegia, what is the diagnosis?",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Neurogenetics",
    "explanation": "Progressive external ophthalmoplegia (PEO) is characterized by slowly progressive weakness of the extraocular muscles, often accompanied by ptosis. In young patients, especially when the condition is insidious and bilateral, a mitochondrial etiology (mitochondrial PEO) is highly suspicious. Mitochondrial disorders result from defects in the mitochondrial DNA that impair oxidative phosphorylation. In mitochondrial PEO, mutations (often large-scale deletions) lead to defective ATP production. As extraocular muscles are highly energy-dependent, even a slight reduction in mitochondrial function results in their early and preferential involvement. Patients present with gradually worsening bilateral ptosis and ophthalmoplegia. Unlike disorders such as myasthenia gravis where weakness fluctuates, mitochondrial PEO typically shows a steady progression. The absence of fluctuating symptoms and additional systemic involvement (in some cases) distinguishes it from other neuromuscular disorders. The workup includes a detailed history, clinical examination, serum lactate/pyruvate levels, and confirmatory tests like muscle biopsy with histochemical staining. Differential diagnoses include myasthenia gravis (which would show fluctuating weakness and response to cholinesterase inhibitors), oculopharyngeal muscular dystrophy (later-onset with dysphagia), thyroid eye disease (associated with proptosis and inflammatory signs), and brainstem lesions (which would often have additional neurological deficits). Genetic testing for mitochondrial DNA mutations may ultimately confirm the diagnosis. There is currently no cure for mitochondrial PEO. Management is largely supportive and includes measures like antioxidant supplementation (e.g., Coenzyme Q10), exercise therapy, and symptomatic treatment. Regular monitoring for potential multisystem involvement is recommended. In pregnancy and lactation, genetic counseling is crucial given the maternal inheritance of mitochondrial DNA, although most management is supportive and does not directly contraindicate pregnancy. Adjustments may be required if systemic involvement affects maternal health. The marked answer (C \u2013 representing mitochondrial PEO) is correct for a young male with PEO. Myasthenia gravis would present with fluctuating symptoms and improvement with rest, oculopharyngeal muscular dystrophy typically has later onset with dysphagia, brainstem lesions are usually accompanied by other neurological deficits, and thyroid eye disease involves additional features such as lid retraction and proptosis. 1. Mitochondrial PEO typically presents with symmetrical, progressive extraocular muscle weakness without fluctuation. 2. A muscle biopsy with ragged red fibers and genetic testing are key in confirming the diagnosis. 3. Mitochondrial disorders are maternally inherited, so family history and genetic counseling are important. Recent advances in noninvasive genetic testing and improved imaging techniques (e.g., MR spectroscopy) have enhanced early detection and characterization of mitochondrial disorders. While no disease-modifying treatments are approved yet, ongoing research into mitochondrial-targeted therapies and antioxidants holds promise for future management.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Same as above Q asked about mutation?",
    "option_a": "Large deletion of mitochondria DNA",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neurogenetics",
    "explanation": "Mitochondrial disorders are often linked to specific mutations in mitochondrial DNA. In cases of PEO, a classic mutation is a large-scale deletion of mitochondrial DNA, which disrupts the function of the oxidative phosphorylation system. Large deletions in mitochondrial DNA result in the loss of genes essential for respiratory chain function. This leads to a decreased ATP production in tissues with high energy demand, such as the extraocular muscles, thereby causing the clinical manifestations of PEO. Patients with mitochondrial PEO often present with slowly progressive, bilateral eye movement impairment. The presence of a large mitochondrial DNA deletion explains the chronic, insidious progression of symptoms and is usually confirmed on muscle biopsy or genetic testing. Initial laboratory testing may include serum lactate and pyruvate levels. Confirmatory diagnosis is achieved through muscle biopsy (demonstrating 'ragged red fibers') and genetic studies that reveal large deletions in mitochondrial DNA. Differential diagnoses include other mitochondrial disorders, metabolic myopathies, and neuromuscular junction disorders (e.g., myasthenia gravis). There is no curative treatment. Management focuses on symptomatic relief and supportive care, including antioxidants (e.g., Coenzyme Q10) and physical therapy. In the setting of pregnancy or lactation, careful genetic counseling is vital due to the maternal inheritance pattern of mitochondrial DNA. Adjustments in supportive care may be needed based on maternal nutritional and metabolic status. Option A (Large deletion of mitochondrial DNA) is correct. Other options, if provided, might include point mutations or less typical alterations; however, the large-scale deletion is the classic genetic abnormality in mitochondrial PEO. This option aligns with data from muscle biopsy and genetic analyses. 1. Remember that large-scale deletions in mitochondrial DNA are a common cause of mitochondrial PEO. 2. Mitochondrial disorders often require a multidisciplinary approach due to possible multi-organ involvement. 3. Genetic testing is central not only for diagnosis but also for counseling regarding maternal inheritance. Recent genetic studies using next-generation sequencing have improved the detection rate of large deletions in mitochondrial DNA. Ongoing research is evaluating potential mitochondrial-targeted therapies, although current management remains supportive and symptomatic.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Case scenario SMA suggestive of AR inheritance asked about the likelihood to be developed in offspring?",
    "option_a": "25% affected",
    "option_b": "25% carriers",
    "option_c": "50% normal",
    "option_d": "50% affected",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neurogenetics",
    "explanation": "Spinal Muscular Atrophy (SMA) is an autosomal recessive disorder that affects the anterior horn cells of the spinal cord leading to progressive muscle weakness. Autosomal recessive inheritance patterns dictate that both parents must be carriers for a 25% chance of each child being affected. SMA is most commonly caused by mutations in the SMN1 gene. The reduction or absence of the survival motor neuron (SMN) protein leads to degeneration of motor neurons, causing muscle atrophy and weakness. The autosomal recessive pattern means that if both parents are carriers, each offspring has a one-in-four risk of being affected. Clinically, SMA presents with hypotonia, muscle weakness, and reduced reflexes. In severe forms (e.g., type I or Werdnig-Hoffmann disease), symptoms present in infancy with significant motor impairment. The straightforward autosomal recessive pattern facilitates genetic counseling regarding recurrence risk. Diagnosis is made via genetic testing for SMN1 gene deletions or mutations. Differential diagnoses include other neuromuscular disorders such as congenital myopathies, muscular dystrophies, or metabolic conditions. A detailed family history and genetic studies help differentiate these conditions. Recent advances include disease-modifying therapies such as nusinersen, onasemnogene abeparvovec, and risdiplam. These are primarily indicated for pediatric patients. In the context of pregnancy and lactation, genetic counseling is essential for carrier parents; while these treatments are not used during pregnancy, planning and pre-conception counseling are important. Supportive care including physical therapy, respiratory support, and nutritional management remains critical. Option A (25% affected) is correct. In autosomal recessive inheritance, each pregnancy has a 25% chance of the child inheriting both copies of the mutant gene, a 50% chance of being a carrier, and a 25% chance of being unaffected. Options suggesting higher percentages of affected offspring or misclassifying carriers are incorrect. 1. In autosomal recessive disorders like SMA, a 25% recurrence risk in offspring is the standard calculation when both parents are carriers. 2. Early genetic diagnosis allows for timely intervention with promising gene therapies. 3. A detailed family history is critical in assessing the risk for autosomal recessive conditions. Breakthroughs in gene therapy and antisense oligonucleotide treatments have significantly altered the management landscape for SMA. Latest clinical guidelines stress early intervention and multidisciplinary care. Genetic counseling remains a cornerstone, particularly for families planning future pregnancies.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Patients presented with symptoms suggestive of mitochondrial disorder, what investigation will be most helpful.",
    "option_a": "Acylcarntine profile",
    "option_b": "Lactate/pyruvate profile",
    "option_c": "Thymidine level",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neurogenetics",
    "explanation": "In mitochondrial disorders, defects in oxidative phosphorylation result in metabolic imbalances. The lactate/pyruvate profile is a key investigation used to screen for disturbances in mitochondrial energy metabolism. Due to impaired mitochondrial function, cells rely more on anaerobic metabolism, leading to an accumulation of lactate relative to pyruvate. An abnormal lactate/pyruvate ratio is a biochemical marker indicative of mitochondrial dysfunction. Patients with suspected mitochondrial disorders often present with multisystem involvement including muscle weakness, neurological deficits, and exercise intolerance. Elevated lactate levels, especially under stress or fasting conditions, are commonly observed. After initial clinical suspicion, the lactate/pyruvate ratio is one of the first biochemical tests performed. Differential diagnoses include other metabolic myopathies, fatty acid oxidation defects (which are more commonly investigated with acylcarnitine profiling), and specific nucleotide metabolism disorders (e.g., thymidine phosphorylase deficiency in MNGIE syndrome). Muscle biopsy and genetic testing generally follow if the biochemical tests are abnormal. Management is primarily supportive, including the administration of vitamins and cofactors (e.g., Coenzyme Q10, riboflavin), tailored exercise programs, and nutritional support. In pregnancy and lactation, careful metabolic monitoring is advised. Genetic counseling is recommended because mitochondrial disorders can have complex inheritance patterns, and maternal transmission is a key consideration. Option B (Lactate/pyruvate profile) is correct because it directly assesses the biochemical consequences of mitochondrial dysfunction. An acylcarnitine profile (Option A) is more suited for fatty acid oxidation disorders, while thymidine level (Option C) is specific to rare conditions such as mitochondrial neurogastrointestinal encephalomyopathy (MNGIE). 1. An elevated lactate/pyruvate ratio is a classic marker of mitochondrial dysfunction. 2. Biochemical testing is often the first step before moving to more invasive testing like muscle biopsy. 3. Mitochondrial disorders are heterogeneous; a normal lactate/pyruvate ratio does not entirely exclude the diagnosis in all cases. Advances in metabolic and genetic testing techniques have improved the sensitivity of mitochondrial disorder diagnoses. Recent studies also emphasize the value of integrated testing approaches (biochemical, histological, and genetic) to provide a definitive diagnosis. New guidelines advocate for a multidisciplinary evaluation to optimize patient management and counseling.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Patient with Marfanoid habitus and lens dislocation. What treatment will you give to him:",
    "option_a": "B6",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neurogenetics",
    "explanation": "Homocystinuria is an inborn error of metabolism most commonly due to cystathionine beta\u2010synthase (CBS) deficiency. Patients often display a Marfanoid habitus with features such as tall stature, long limbs, and lens dislocation (classically downward). This condition is distinct from Marfan syndrome despite some overlapping physical features. In homocystinuria, the inability of CBS to convert homocysteine to cystathionine results in the accumulation of homocysteine in plasma. The toxic effects of high homocysteine levels contribute to connective tissue abnormalities, ocular changes (lens dislocation), skeletal malformations, and a prothrombotic state. In many patients, the enzyme retains some activity when provided with higher levels of its cofactor, pyridoxine (vitamin B6), making a B6 trial a first\u2010line intervention in pyridoxine-responsive cases. The patient presents with a Marfanoid body habitus and lens dislocation, which should raise suspicion for homocystinuria rather than Marfan syndrome (which typically has upward lens dislocation and lacks the high thrombotic risk). Other associated features include intellectual disability and an increased risk of thromboembolic events. Diagnosis is established by measuring plasma homocysteine and methionine levels and confirmed by identification of CBS gene mutations. Differential diagnoses include Marfan syndrome and Ehlers\u2013Danlos syndrome; these can be distinguished based on lens dislocation direction, laboratory values, and genetic testing. The mainstay of treatment for homocystinuria caused by CBS deficiency is **pyridoxine (vitamin B6) supplementation**, which serves as a cofactor for CBS enzyme and can enhance residual enzyme activity in B6-responsive patients. According to the 2021 guidelines from the American College of Medical Genetics and Genomics (ACMG):  \"Initial management of homocystinuria includes high-dose pyridoxine therapy to identify responsiveness, combined with dietary methionine restriction and supplementation with betaine if needed. Early and aggressive treatment reduces the risk of thromboembolism and improves neurological outcomes.\"  First-line treatment: - High-dose vitamin B6 (pyridoxine) to enhance CBS activity. - Low-methionine diet to reduce substrate load. - Folic acid and vitamin B12 supplementation to support remethylation pathways.  Second-line treatment: - Betaine therapy to promote remethylation of homocysteine to methionine in B6-nonresponsive patients. - Antiplatelet or anticoagulation therapy for thromboembolism prevention.  Mechanistically, pyridoxine acts as a coenzyme for CBS, improving conversion of homocysteine to cystathionine, thereby lowering homocysteine levels and ameliorating clinical manifestations. Long-term management includes monitoring homocysteine levels and preventing complications. Option A: B6 (Pyridoxine) \u2013 Correct - This is the cornerstone treatment for homocystinuria due to CBS deficiency, especially in B6-responsive patients. It enhances residual enzyme activity, reduces homocysteine levels, and prevents complications.  Incorrect options (not listed here but generally would include): - Betaine: Used in B6-nonresponsive cases but not first-line. - Vitamin C or E: No role in treating homocystinuria. - Surgical correction of lens dislocation: May be needed but does not address underlying metabolic defect.  Since only option A is provided and is correct, the key is recognizing that vitamin B6 supplementation treats the underlying enzymatic defect. Other treatments are adjunctive or supportive. The discriminating feature is that B6 directly targets the metabolic cause, unlike symptomatic or supportive options. - Always consider homocystinuria in patients with marfanoid habitus and lens dislocation, especially if neurological symptoms or thromboembolism are present. - Lens dislocation in homocystinuria is typically inferonasal, contrasting with the superotemporal dislocation in Marfan syndrome. - Early initiation of pyridoxine can prevent irreversible neurological and vascular complications. - Measure plasma homocysteine levels in any patient with marfanoid features and ocular abnormalities. - Remember that not all patients respond to B6; genetic testing and enzyme assays guide therapy. - Avoid misdiagnosing homocystinuria as Marfan syndrome, as management differs significantly. - Incorporate multidisciplinary care including neurology, genetics, ophthalmology, and nutrition. The 2021 American College of Medical Genetics and Genomics (ACMG) guideline on homocystinuria states: \"Pyridoxine responsiveness should be assessed in all patients diagnosed with CBS deficiency. High-dose pyridoxine therapy remains the first-line treatment and can significantly improve clinical outcomes if started early.\" (ACMG Practice Guideline, 2021)  Recent studies emphasize early newborn screening and prompt treatment initiation to reduce morbidity. Knowledge gaps remain regarding optimal long-term management and monitoring. New therapies under investigation include enzyme replacement and gene therapy, but these are not yet clinically available.  Controversies include the variable response to B6 and the role of betaine in different populations. Current consensus favors individualized treatment based on biochemical and genetic profiling.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Not sure if it\u2019s right but a patient with FA features asked about the gene?",
    "option_a": "GAA",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "FXN",
    "subspecialty": "Neurogenetics",
    "explanation": "Friedreich's ataxia (FA) is an autosomal recessive neurodegenerative disorder that primarily affects the spinal cord, cerebellum, and peripheral nerves. It typically presents in childhood or adolescence with gait ataxia, dysarthria, loss of proprioception, and often cardiomyopathy. The disease is caused by a GAA trinucleotide repeat expansion within the first intron of the FXN gene. This mutation leads to a marked reduction in the expression of frataxin, a mitochondrial protein vital for iron regulation. The resulting iron accumulation leads to oxidative stress and mitochondrial dysfunction, which underlie the clinical manifestations of FA. Patients with FA present with progressive ataxia, dysarthria, and sensory deficits and often develop complications such as hypertrophic cardiomyopathy and diabetes mellitus. These characteristic features, along with a positive family history, prompt genetic testing to confirm the diagnosis. The definitive diagnosis of Friedreich's ataxia relies on molecular genetic testing, which reveals a pathogenic expansion of GAA repeats in the FXN gene. Key differential diagnoses may include other hereditary ataxias (such as spinocerebellar ataxias), vitamin deficiencies, or acquired cerebellar degeneration. A detailed neurologic exam, cardiac evaluation, and genetic counseling form the cornerstone of the diagnostic work-up. There is no cure for FA; management is primarily supportive and multidisciplinary. Interventions include physical and occupational therapy, tailored exercise programs, and careful cardiac monitoring and treatment. For patients who are pregnant or lactating, management strategies remain supportive with special attention to potential cardiovascular complications, and genetic counseling is crucial for family planning. Medications must be chosen with caution, considering teratogenicity and drug safety in lactation, in accordance with current guidelines. Option A presented 'GAA', which refers to the trinucleotide repeat that is expanded in the disease. However, when asked about the gene implicated in FA, the correct answer is FXN, not 'GAA'. Therefore, although 'GAA' reflects the nature of the mutation, the gene's name is FXN. \u2022 Friedreich's ataxia is characterized by a GAA repeat expansion in the FXN gene, leading to frataxin deficiency. \n\u2022 Recognize that the term 'GAA' in this context describes the mutation, not the gene itself. \n\u2022 Multidisciplinary care is essential, especially in managing cardiomyopathy and coordinating genetic counseling for affected families, including those considering pregnancy or who are lactating. Recent research continues to explore therapies that might upregulate frataxin or address mitochondrial dysfunction. However, current treatment remains supportive. Emerging gene therapy trials are underway, and guidelines emphasize early diagnosis and a comprehensive management plan. In pregnant or lactating patients, careful coordination of care and review of current teratogenicity data are essential as per the latest clinical recommendations.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Case scenario typical for FTD-ALS. What gene?",
    "option_a": "SOD1",
    "option_b": "C9ORF72",
    "option_c": "SOD2",
    "option_d": "MAPT",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neurogenetics",
    "explanation": "Frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) are neurodegenerative disorders that sometimes coexist in a clinical spectrum. Approximately 10\u201315% of patients with ALS exhibit features of FTD, and genetic studies have demonstrated that a hexanucleotide repeat expansion in the C9ORF72 gene is the most common genetic abnormality linking these two conditions. The C9ORF72 mutation involves a hexanucleotide (GGGGCC) repeat expansion in a non-coding region of the gene. This expansion leads to the production of toxic RNA foci and dipeptide repeat proteins, which can interfere with normal cellular functions and contribute to neuronal degeneration. The pathology associated with C9ORF72 mutations is seen in both the frontal/temporal lobes (FTD) and motor neurons (ALS). Patients with FTD-ALS typically present with behavioral changes, language difficulties, and executive dysfunction (characteristics of FTD), in conjunction with signs of motor neuron degeneration such as muscle weakness, atrophy, fasciculations, and spasticity (characteristics of ALS). The presence of a C9ORF72 mutation is strongly correlated with this overlapping clinical picture. A detailed clinical evaluation including neuropsychological assessments for FTD and electromyography (EMG) for ALS features is essential. Genetic testing for the C9ORF72 repeat expansion is recommended in patients with an FTD-ALS phenotype, particularly in those with a significant family history. Neuroimaging (MRI) may also be used to assess atrophy patterns in the frontal and temporal lobes. There is currently no cure for FTD-ALS, and management is primarily supportive. For ALS, FDA-approved treatments such as riluzole and edaravone may be used to slow disease progression. Symptomatic treatments for cognitive and behavioral symptoms in FTD may include selective serotonin reuptake inhibitors (SSRIs) and other supportive therapies. For patients of reproductive age, including pregnant or lactating women, genetic counseling is essential to discuss the risks of transmission and explore reproductive options. Management should be individualized and supportive, emphasizing quality of life and multidisciplinary care. Option A (SOD1) is associated with familial ALS but does not commonly present with FTD. Option C (SOD2) is not typically implicated in these disorders. Option D (MAPT) is implicated in familial FTD but is not linked with ALS. Therefore, Option B (C9ORF72) is correctly identified as the gene implicated in the FTD-ALS phenotype. \u00b7 The C9ORF72 hexanucleotide repeat expansion is the most common genetic abnormality in the FTD-ALS spectrum.  \n\u00b7 Both clinical and family history are essential in raising suspicion for a genetic etiology.  \n\u00b7 Multidisciplinary management including genetic counseling is crucial, particularly for affected individuals of childbearing potential. Recent research continues to solidify the role of C9ORF72 in the pathogenesis of combined FTD and ALS. Advances in genetic testing have led to its widespread adoption in clinical settings, and emerging studies are exploring targeted therapeutics that may mitigate the toxic effects of the repeat expansion.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Patient has ataxia and other neurological features, all the men in family affected (X linked pattern). What is the diagnosis?",
    "option_a": "Adrenomyeloneuropathy",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neurogenetics",
    "explanation": "This condition is a variant of X-linked adrenoleukodystrophy (X-ALD) known as adrenomyeloneuropathy. X-ALD disorders are caused by mutations in the ABCD1 gene, leading to a failure in peroxisomal beta\u2010oxidation of very long chain fatty acids, with resultant accumulation in various tissues. The X-linked pattern is confirmed by the fact that only males in the family are affected. Adrenomyeloneuropathy results from a mutation in the ABCD1 gene, impairing peroxisomal degradation of very long chain fatty acids. The toxic buildup of these fatty acids leads to demyelination in the central nervous system, adrenal cortex dysfunction, and progressive neurological decline. Patients typically present in adulthood with symptoms such as gait disturbances, ataxia, spastic paraparesis, and peripheral neuropathy. The involvement of adrenal insufficiency may lead to endocrine manifestations. The X-linked inheritance pattern, where nearly all affected individuals are males, further supports the diagnosis. Diagnosis involves a combination of family history, neurological examination, biochemical assays (notably elevated serum very long chain fatty acids), adrenal function testing, and imaging studies (MRI demonstrating white matter changes). The pedigree showing male-only involvement is a critical clue in confirming an X-linked disorder. There is no cure for adrenomyeloneuropathy; management is mainly supportive and focuses on symptom control and hormonal replacement if adrenal insufficiency is present. Hematopoietic stem cell transplantation may be considered in early cerebral forms but is generally not applicable to the adrenomyeloneuropathy variant. For pregnant or lactating women who may be carriers or require genetic counseling, careful monitoring is advisable. Endocrine and neurologic surveillance is critical, and treatment regimens should avoid teratogenic agents while ensuring maternal and fetal safety. Option A, Adrenomyeloneuropathy, best explains the clinical scenario. Although the question has incomplete options, the presence of an X-linked inheritance pattern in a patient with ataxia and neurological features strongly supports this diagnosis. 1. An X-linked pattern of inheritance, with affected males in a pedigree, is a key clue. 2. Elevated levels of very long chain fatty acids are diagnostic of X-ALD variants. 3. Neurological features in adrenomyeloneuropathy may include ataxia, spasticity, and peripheral neuropathy, distinguishing it from other ataxias which might have autosomal modes of inheritance. Current clinical guidelines emphasize early biochemical diagnosis and the role of supportive management, including adrenal hormone replacement and symptomatic treatment. Investigational therapies targeting peroxisomal function are under evaluation. Genetic counseling remains an essential component, especially for families with known X-linked disorders. Considerations during pregnancy or lactation involve multidisciplinary oversight to manage endocrine or neurological complications without exposing the patient or fetus to prohibitive risks.",
    "exam_year": "2022",
    "exam_type": "Part I"
  }
]